Tissue Array
Log In | My Account | Cart (0 items) - $0.00
US Biomax, Inc.
 

FCO401

Colorectal organ carcinoma frozen tissue array, including TNM, clinical stage, 40 cases/40 cores, replaced by FCO401a
Unstained: $495.00 Add to Cart
H&E (FCO401s*): $495.00 Add to Cart

Microarray Panel:Colorectal organ carcinoma frozen tissue microarray, containing 13 cases of rectum carcinoma and 27 cases of colon carcinoma , single core per case
Cores:40
Cases:40
Layout:8 cols × 5 rows
Core Diameter:2 mm
Thickness:5 µm
Quality Control:Anti-Actin confirmed
Applications:Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:Tissues were snap frozen in liquid nitrogen immediately after excision and were embedded in OCT. The array sections are 5-8 µm in thickness, mounted on positively charged glass slides, and briefly fixed by cold acetone.

*Tissue Microarray Slide Types:

  • Unstained: unstained frozen tissue microarray slide.
  • Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
  • H & E: Hematoxylin and Eosin stained tissue microarray slide.

Microarray Panel Display

 
Slide Label: US Biomax, Inc. Tissue Array
12345678
A Rec Rec Rec Rec Rec Rec Rec Rec
B Rec Rec Rec Rec Rec Col Col Col
C Col Col Col Col Col Col Col Col
D Col Col Col Col Col Col Col Col
E Col Col Col Col Col Col Col Col
Legend: Col - Colon, Rec - Rectum

- Malignant tumor (stage I), - Malignant tumor (stage II), - Malignant tumor (stage III), - Malignant tumor (stage IIIa)

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Stage TNM Type †
A1 1 M 62 Rectum Mucinous adenocarcinoma(sparse) III T3N1M0 Malignant
A2 2 M 69 Rectum Adenocarcinoma III T3N1M0 Malignant
A3 3 M 42 Rectum Adenocarcinoma II T3N0M0 Malignant
A4 4 M 40 Rectum Adenocarcinoma II T3N0M1 Malignant
A5 5 F 42 Rectum Adenocarcinoma II T3N0M0 Malignant
A6 6 M 57 Rectum Adenocarcinoma II T3N0M1 Malignant
A7 7 M 41 Rectum Adenocarcinoma II T3N0M0 Malignant
A8 8 M 58 Rectum Adenocarcinoma II T3N0M0 Malignant
B1 9 M 45 Rectum Adenocarcinoma I T3N0M0 Malignant
B2 10 M 67 Rectum Adenocarcinoma I T2N0M0 Malignant
B3 11 M 66 Rectum Adenocarcinoma II T3N0M0 Malignant
B4 12 M 40 Rectum Adenocarcinoma II T3N0M0 Malignant
B5 13 F 62 Rectum Squamous cell carcinoma III T3N1M0 Malignant
B6 14 M 44 Colon Adenocarcinoma II T3N0M0 Malignant
B7 15 F 60 Colon Adenocarcinoma III T3N1M0 Malignant
B8 16 F 50 Colon Adenocarcinoma II T3N0M0 Malignant
C1 17 M 48 Colon Adenocarcinoma III T3N1M0 Malignant
C2 18 M 60 Colon Adenocarcinoma II T3N0M0 Malignant
C3 19 F 67 Colon Adenocarcinoma II T3N0M1 Malignant
C4 20 M 46 Colon Adenocarcinoma III T3N1M0 Malignant
C5 21 F 70 Colon Adenocarcinoma II T3N0M0 Malignant
C6 22 M 48 Colon Adenocarcinoma III T3N1M0 Malignant
C7 23 F 49 Colon Adenocarcinoma(smooth muscle) II T3N0M0 Malignant
C8 24 M 45 Colon Adenocarcinoma II T3N0M1 Malignant
D1 25 M 45 Colon Adenocarcinoma II T3N0M2 Malignant
D2 26 M 58 Colon Adenocarcinoma III T3N1M0 Malignant
D3 27 M 59 Colon Adenocarcinoma II T3N0M0 Malignant
D4 28 M 55 Colon Adenocarcinoma II T3N0M0 Malignant
D5 29 M 39 Colon Adenocarcinoma II T3N0M0 Malignant
D6 30 F 43 Colon Adenocarcinoma II T3N0M1 Malignant
D7 31 F 41 Colon Adenocarcinoma II T3N0M2 Malignant
D8 32 M 67 Colon Adenocarcinoma II T3N0M0 Malignant
E1 33 M 50 Colon Adenocarcinoma III T3N1M0 Malignant
E2 34 M 75 Colon Adenocarcinoma II T3N0M0 Malignant
E3 35 M 52 Colon Adenocarcinoma III T3N1M0 Malignant
E4 36 M 62 Colon Adenocarcinoma(sparse) I T2N0M0 Malignant
E5 37 M 43 Colon Adenocarcinoma III T3N1M0 Malignant
E6 38 M 37 Colon Adenocarcinoma III T3N1M0 Malignant
E7 39 F 42 Colon Interstitialoma III T3N1M0 Malignant
E8 40 F 38 Colon Interstitialoma IIIa T3N1M0 Malignant

† For precise diagnosis, refer to pathology description.

TNM Grading

Primary tumor (T)

  • TX: Primary tumor cannot be assessed
  • T0: No evidence of primary tumor
  • Tis: Intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple with no associated invasion of normal breast tissue
    • Tis (DCIS): Ductal carcinoma in situ
    • Tis (LCIS): Lobular carcinoma in situ
    • Tis (Paget's): Paget's disease of the nipple with no tumor. [Note: Paget's disease associated with a tumor is classified according to the size of the tumor.]
  • T1: Tumor 2.0 cm or less in greatest dimension
    • T1mic: Microinvasion 0.1 cm or less in greatest dimension
    • T1a: Tumor more than 0.1 but not more than 0.5 cm in greatest dimension
    • T1b: Tumor more than 0.5 cm but not more than 1.0 cm in greatest dimension
    • T1c: Tumor more than 1.0 cm but not more than 2.0 cm in greatest dimension
  • T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension
  • T3: Tumor more than 5.0 cm in greatest dimension
  • T4: Tumor of any size with direct extension to (a) chest wall or (b) skin, only as described below.
    • T4a: Extension to chest wall, not including pectoralis muscle
    • T4b: Edema (including peau d'orange) or ulceration of the skin of the breast, or satellite skin nodules confined to the same breast
    • T4c: Both T4a and T4b
    • T4d: Inflammatory carcinoma.
  • Memory Aid for Primary tumor: The two numbers to remember are 2.0 and 5.0
    • T1 is no larger than 2.0 cm
    • T2 > 2.0 - 5.0 cm
    • T3 > 5.0 cm

Regional lymph nodes (N)

  • NX: Regional lymph nodes cannot be assessed (e.g., previously removed)
  • N0: No regional lymph node metastasis
  • N1: Metastasis to movable ipsilateral axillary lymph node(s)
  • N2: Metastasis to ipsilateral axillary lymph node(s) fixed or matted, or in clinically apparent* ipsilateral internal mammary notes in the absence of clinically evident lymph node metastasis
    • N2a: Metastasis in ipsilateral axillary lymph nodes fixed to one another (matted) or to other structures
    • N2b: Metastasis only in clinically apparent* ipsilateral internal mammary nodes and in the absence of clinically evident axillary lymph node metastasis.
  • N3: Metastasis in ipsilateral infraclavicular lymph node(s) with or without axillary lymph node involvement, or in clinically apparent* ipsilateral internal mammary lymph node(s) and in the presence of clinically evident axillary lymph node metastasis; or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement
    • N3a: Metastasis in ipsilateral infraclavicular lymph node(s)
    • N3b: Metastasis in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)
    • N3c: Metastasis in ipsilateral supraclavicular lymph node(s)

* [Note: Clinically apparent is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination or grossly visible pathologically.]

Distant metastasis (M)

  • MX: Presence of distant metastasis cannot be assessed
  • M0: No distant metastasis
  • M1: Distant metastasis

Find overlapping cases with this tissue array:
© 2003 - 2011 US Biomax Inc., custsrv@biomax.us, Tel: (800) 935-1357 | Privacy Policy

Authorize.Net Seal Starfield Seal